Unicycive Therapeutics Inc Stock
Unicycive Therapeutics Inc Stock price
Key metrics
| Market capitalization | $72.38m |
| Enterprise Value | $53.16m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 6.37 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-30.90m |
| Free Cash Flow (TTM) Free Cash Flow | $-31.10m |
| Cash position | $19.77m |
Is Unicycive Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Unicycive Therapeutics Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Unicycive Therapeutics Inc forecast:
Analyst Opinions
7 Analysts have issued a Unicycive Therapeutics Inc forecast:
Financial data from Unicycive Therapeutics Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.39 -0.39 |
25%
25%
|
|
| EBITDA | -31 -31 |
21%
21%
|
EBIT (Operating Income) EBIT | -31 -31 |
20%
20%
|
| Net Profit | -21 -21 |
43%
43%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Unicycive Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Unicycive Therapeutics Inc Stock News
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
| Head office | United States |
| CEO | Shalabh Gupta |
| Employees | 22 |
| Founded | 2016 |
| Website | www.unicycive.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
